Person: AYDIN GÜÇLÜ, ÖZGE
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
AYDIN GÜÇLÜ
First Name
ÖZGE
Name
19 results
Search Results
Now showing 1 - 10 of 19
Publication Response to "Hypercapnic respiratory failure with insufficient response to fixed- level PS-NIV: Is AVAPS the end solution?"(Turkish Assoc Tuberculosis & Thorax, 2023-01-01) Öztürk, Nilüfer Aylin Acet; Güçlü, Özge Aydın; Demirdoğen, Ezgi; Dilektaşlı, Aslı Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; Z-1424-2019; AAG-9930-2019; AAH-9812-2021; DTT-7416-2022; DDT-7334-2022; AAD-1271-2019; CDI-1977-2022; AAG-8744-2021Publication Development and validation of a simple risk scoring system for a COVİD-19 diagnostic prediction model(Tüberküloz ve Toraks, 2023-01-01) Güçlü, Özge Aydın; Ursavaş, Ahmet; Ocakoğlu, Gokhan; Demirdogen, Ezgi; Öztürk, Nilufer Aylin Acet; Topçu, Dilara Ömer; Terzi, Orkun Eray; Onal, Uğur; Dilektaşlı, Aslı Görek; Sağlık, İmran; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; AkalIn, Halis; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; OCAKOĞLU, GÖKHAN; DEMİRDÖĞEN, EZGİ; ACET ÖZTÜRK, NİLÜFER AYLİN; ÖMER TOPÇU, DİLARA; TERZİ, ORKUN ERAY; ÖNAL, UĞUR; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; AkalIn, Halis; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı; 0000-0003-1005-3205; 0000-0002-1114-6051; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-2954-4293; 0000-0001-7530-1279; 0000-0002-9027-1132; AAH-5180-2021; A-4970-2019; AAG-8744-2021; AAI-3169-2021; JCO-3678-2023; JPK-7012-2023Introduction: In a resource-constrained situation, a clinical risk stratification system can assist in identifying individuals who are at higher risk and should be tested for COVID-19. This study aims to find a predictive scoring model to estimate the COVID-19 diagnosis.Materials and Methods: Patients who applied to the emergency pandemic clinic between April 2020 and March 2021 were enrolled in this retrospective study. At admission, demographic characteristics, symptoms, comorbid diseases, chest computed tomography (CT), and laboratory findings were all recorded. Development and validation datasets were created. The scoring system was performed using the coefficients of the odds ratios obtained from the multivariable logistic regression analysis.Results: Among 1187 patients admitted to the hospital, the median age was 58 years old (22-96), and 52.7% were male. In a multivariable analysis, typical radiological findings (OR= 8.47, CI= 5.48-13.10, p< 0.001) and dyspnea (OR= 2.85, CI= 1.71-4.74, p< 0.001) were found to be the two important risk factors for COVID-19 diagnosis, followed by myalgia (OR= 1.80, CI= 1.082.99, p= 0.023), cough (OR= 1.65, CI= 1.16-2.26, p= 0.006) and fatigue symptoms (OR= 1.57, CI= 1.06-2.30, p= 0.023). In our scoring system, dyspnea was scored as 2 points, cough as 1 point, fatigue as 1 point, myalgia as 1 point, and typical radiological findings were scored as 5 points. This scoring system had a sensitivity of 71% and a specificity of 76.3% for a cut-off value of >2, with a total score of 10 (p< 0.001).Conclusion: The predictive scoring system could accurately predict the diagnosis of COVID-19 infection, which gave clinicians a theoretical basis for devising immediate treatment options. An evaluation of the predictivePublication Relationship with excessive daytime sleepiness and serum substance P levels in OSAS patients and the effect of PAP treatment(Springer Japan, 2019-07-01) Güçlu, Özge Aydın; Ursavaş, Ahmet; Kasapoğlu, Fikret; Özarda, Yeşim; Bozyiğit, Cengiz; Ocakoğlu, Gökhan; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; KASAPOĞLU, FİKRET; ÖZARDA, YEŞİM; BOZYİĞİT, CENGİZ; OCAKOĞLU, GÖKHAN; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kulak Burun Boğaz Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0003-1005-3205; 0000-0003-2215-6973; 0000-0002-1114-6051; 0000-0002-9027-1132; AAI-3877-2021; AAI-3169-2021; AAH-5180-2021; AAL-8873-2021; HLG-6346-2023; AAG-8744-2021; AAG-9930-2019; AAE-1623-2022Obstructive sleep apnea syndrome (OSAS) is a commonly seen disorder characterized by repeated episodes of upper airway obstruction during sleep leading to intermittent hypoxemia or arousal. We aim to evaluate the effects of positive airway pressure (PAP) treatment on daytime sleepiness and serum Substance P (SP) levels in OSAS patients. Seventy-one consecutive patients with newly diagnosed OSAS and 19 non-apneic control subjects were enrolled to the study. PAP treatment indicated subjects were re-evaluated after 3 months of treatment. Morning SP levels of OSAS patients and Epworth sleepiness scale (ESS) were assessed at the beginning and then after 3 months of PAP treatment. Of the patients 71 (78.9%) were male and 19 (21.1%) were female, with a median age of 45 [20-62]. The levels of SP in the OSAS group were significantly lower than the snorer group and a significant correlation was not found between serum levels of SP and ESS. SP levels were negatively correlated with AHI. The baseline SP median was 336.1pg/mL [121.6-536.1], while the 3rd month SP median was 213.1pg/mL [103.5-727.6]. Serum SP values were found to have significantly decreased at 3months (p<0.0001). Statistically significant correlation was not found between percentage of ESS change and the percentage of SP change. It can be assumed that the SP level is reduced as part of the compensation mechanism in OSAS cases and supporting this mechanism, the PAP therapy further reduces the SP value by relieving the cases from apnea and the intermittent hypoxia burden.Publication AVAPS-NIV treatment in hypercapnic respiratory failure with insufficient response to fixed-level PS-NIV(Türk Tüberküloz ve Toraks, 2022-01-01) Öztürk, Nilüfer Aylın Acet; Güçlü, Özge Aydın; Demirdöğen, Ezgi; Dilektaşlı, Asli Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; URSAVAŞ, AHMET; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; DTT-7416-2022; DDT-7334-2022Introduction: Noninvasive ventilation (NIV) for acute hypercapnic respiratory failure (AHRF) is an established treatment modality. Current evidence does not conclude any superiority between fixed pressure support (PS) and aver-age volume-assured pressure support (AVAPS) modes. However, given the ability of rapid PaCO2 decline in AVAPS mode, we hypothesized that COPD patients with AHRF who did not show the desired reduction in PaCO2 with fixed-level PS-NIV might benefit from the AVAPS mode.Materials and Methods: Patients admitted to the non-ICU pulmonary ward with acute exacerbation of COPD (AECOPD) and AHRF were included con-secutively in this observational study. Patients with hypercapnic respiratory failure due to obesity-hypoventilation, neurological diseases, or chest wall deformities were excluded. All patients started NIV treatment with fixed pres-sure support (PS) and patients who did not reach clinical and laboratory stability under PS-NIV treatment were switched to the average volume -as-sured pressure support (AVAPS) mode of NIV.Results: Thirty-five COPD patients with hypercapnic respiratory failure were included. Under PS-NIV treatment, 14 (40%) patients showed a 17.9 (-0.0-29.2) percent change in terms of PaCO2 , meaning no improvement or worsening. Therefore, these patients were treated with AVAPS mode. Arterial PaCO2 and pH levels significantly improved after AVAPS-NIV administration. AVAPS-NIV treatment created a significantly better PaCO2 change rate than using PS-NIV (-11.4 (-22.0 --0.5)vs 8.2 (-5.3-19.5), p= 0.02]. Independent predictors of AVAPS mode requirement were higher Charlson Comorbidity Index (OR= 1.74 (95% CI= 1.02-2.97)] and higher PaCO2 upon admission (OR= 1.18 (95% CI= 1.03-1.35)]. Thirteen (92.8%) patients reaching signif-icant clinical stability with AVAPS-NIV were able to return to fixed-level PS-NIV and maintain acceptable PaCO2 levels.Conclusion: Our study demonstrated that patients can benefit from AVAPS-NIV despite insufficient response to fixed-level PS-NIV.Publication Frailty: An indicator for poor outcomes among in-hospital pulmonology patients(European Respiratory Soc Journals, 2021-09-05) Öztürk, Nilüfer Aylin Acet; Dilektaşlı, Aslı Görek; Güçlü, Özge Aydın; Ursavaş, Ahmet; Demirdoğen, Ezgi; Coşkun, Funda; Uzaslan, Esra; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; GÖREK DİLEKTAŞLI, ASLI; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; JPK-7012-2023; AAG-8744-2021; AAD-1271-2019; Z-1424-2019; CNP-1063-2022; AAG-9930-2019; CDI-1977-2022Publication Prognostic factors for COVID-19 patients(J Infection Developing Countries, 2022-03-01) Önal, Uğur; Güçlü, Özge Aydın; Akalın, Halis; Öztürk, Nilüfer Aylin Acet; Semet, Cihan; Demirdoğen, Ezgi; Dilektaşlı, Aslı Görek; Sağlık, İmran; Kazak, Esra; Özkaya, Güven; Coşkun, Funda; Ediger, Dane; Heper, Yasemin; Ursavaş, Ahmet; Yılmaz, Emel; Uzaslan, Esra; Karadağ, Mehmet; ÖNAL, UĞUR; AYDIN GÜÇLÜ, ÖZGE; AKALIN, EMİN HALİS; ACET ÖZTÜRK, NİLÜFER AYLİN; SEMET, CİHAN; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; KAZAK, ESRA; ÖZKAYA, GÜVEN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; HEPER, YASEMİN; URSAVAŞ, AHMET; YILMAZ, EMEL; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0001-6194-3254; 0000-0003-1005-3205; 0000-0001-7530-1279; 0000-0002-6375-1472; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-0864-4989; 0000-0003-0297-846X; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0002-3894-1231; 0000-0002-9027-1132; A-4421-2016; AAG-8459-2021; GCM-3391-2022; DTT-7416-2022; AAH-9812-2021; AEA-4817-2022; Z-1424-2019; AAU-8952-2020; AAG-9930-2019; ACQ-7832-2022; AAD-1271-2019; AAE-9142-2019; CTY-9474-2022; AAI-3169-2021; HJZ-6992-2023; CDI-1977-2022; AAG-8744-2021Introduction: Determining prognostic factors in patients with coronavirus disease (COVID-19) can have great impact on treatment planning and follow-up strategies. Herein, we aimed to evaluate prognostic factors and clinical scores for confirmed COVID-19 patients in a tertiary care hospital in the Bursa region of Turkey. Methodology: Patients who had been diagnosed with COVID-19 microbiologically and/or radiologically between March and October 2020 in a tertiary-care university hospital were enrolled retrospectively. Adult patients (>= 18 years) with a clinical spectrum of moderate, severe, or critical illness were included. The dependent variable was 30-day mortality and logistic regression analysis was used to evaluate any variables with a significant p value (< 0.05) in univariate analysis. Results: A total of 257 patients were included in the study. The mortality rate (30-day) was 14.4%. In logistic regression analysis, higher scores on sequential organ failure assessment (SOFA) (p < 0.001, odds ratio (OR) = 1.86, 95% CI = 1.42-2.45) and CURB-65 pneumonia severity criteria (p = 0.001, OR = 2.60, 95% CI = 1.47-4.57) were found to be significant in predicting mortality at admission. In deceased patients, there were also significant differences between the baseline, day-3, day-7, and day-14 results of D-dimer (p = 0.01), ferritin (p = 0.042), leukocyte (p = 0.019), and neutrophil (p = 0.007) counts. Conclusions: In our study of COVID-19 patients, we found that high SOFA and CURB-65 scores on admission were associated with increased mortality. In addition, D-dimer, ferritin, leukocyte and neutrophil counts significantly increased after admission in patients who died.Publication Pilot study for immunoglobulin E as a prognostic biomarker in coronavirus disease 2019(Wiley, 2022-08-19) Güçlü, Özge Aydın; Göktaş, Seda S.; Dilektaşlı, Aslı Görek; Öztürk, Nilüfer A. Acet; Demirdoğen, Ezgi; Coşkun, Funda; Ediger, Dane; Ursavaş, Ahmet; Uzaslan, Esra; Erol, Haşim A.; Karacay, Nurdan D.; Sel, Umut Kaya; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; GÖREK DİLEKTAŞLI, ASLI; ACET ÖZTÜRK, NİLÜFER AYLİN; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; URSAVAŞ, AHMET; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünoloji ve Alerji Hastalıkları Bilim Dalı.; 0000-0003-3604-8826 ; 0000-0002-9027-1132 ; 0000-0002-7400-9089 ; 0000-0002-6375-1472 ; 0000-0003-1005-3205 ; AAG-9930-2019; DTT-7416-2022; Z-1424-2019; AAH-9812-2021; AAD-1271-2019; AAE-9142-2019; AAI-3169-2021; CDI-1977-2022; AAG-8744-2021Background Laboratory biomarkers to estimate the severity of coronavirus disease 2019 (COVID-19) are crucial during the pandemic since resource allocation must be carefully planned. Aims To evaluate the effects of basal serum total immunoglobulin E (IgE) levels and changes in inflammatory parameters on the clinical progression of patients hospitalised with COVID-19. Methods Patients hospitalised with confirmed COVID-19 were included in the study. Laboratory data and total IgE levels were measured on admission. Lymphocyte, eosinophil, ferritin, d-dimer and C-reactive protein parameters were recorded at baseline and on the 3rd and 14th days of hospitalisation. Results The study enrolled 202 patients, of which 102 (50.5%) were males. The average age was 50.17 +/- 19.68 years. Of the COVID-19 patients, 41 (20.3%) showed clinical progression. Serum total IgE concentrations were markedly higher (172.90 (0-2124) vs 38.70 (0-912); P < 0.001) and serum eosinophil levels were significantly lower (0.015 (0-1.200) vs 0.040 (0-1.360); P = 0.002) in clinically worsened COVID-19 patients when compared with stable patients. The optimal cut-off for predicting clinical worsening was 105.2 ng/L, with 61% sensitivity, 82% specificity, 46.3% positive predictive value and 89.2% negative predictive value (area under the curve = 0.729). Multivariable analysis to define risk factors for disease progression identified higher total IgE and C-reactive protein levels as independent predictors. Conclusions Our single-centre pilot study determined that total IgE levels may be a negative prognostic factor for clinical progression in patients hospitalised due to COVID-19 infection. Future studies are required to determine the impact of individuals' underlying immune predispositions on outcomes of COVID-19 infections.Publication Effect of asbestos exposure on the frequency of egfr mutations and alk/ros1 rearrangements in patients with lung adenocarcinoma a multicentric study(Lippincott Williams & Wilkins, 2021-03-01) Yilmaz, Senay; Demirci, Nilgun Yilmaz; Metintas, Selma; Zamani, Adil; Kabalak, Pinar Akin; Yilmaz, Ulku; Ak, Guntulu; Kizilgoz, Derya; Ozturk, Akin; Yilmaz, Ufuk; Batum, Ozgur; Kavas, Murat; Serifoglu, Irem; Unsal, Meftun; Komurcuoglu, Berna E.; Cengiz, Tuba Inal; Ulubay, Gaye; Ozdemirel, Tugce S.; Ozyurek, Berna A.; Kavurgaci, Suna; Alizoroglu, Dursun; Celik, Pinar; Erdogan, Yurdanur; In, Erdal; Aksoy, Asude; Altin, Sedat; Gunluoglu, Gulsah; Metintas, Muzaffer; Karadag, Mehmet; KARADAĞ, MEHMET; Guclu, Ozge A.; AYDIN GÜÇLÜ, ÖZGE; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-0523-7819; 0000-0001-6160-3778; 0000-0002-9027-1132; 0000-0003-1005-3205; 0000-0001-8849-193X; 0000-0002-3445-3804; 0000-0002-2806-4781; 0000-0002-2877-242X; 0000-0003-1596-0082; 0000-0003-0206-7615; 0000-0002-8807-5853; 0000-0002-5609-9658; HKN-2974-2023; HNT-0352-2023; AAS-6628-2021; AAG-9930-2019; AFT-6588-2022; AET-7187-2022; D-2127-2014; JWA-4269-2024; AFP-3587-2022; HLH-3244-2023; C-9348-2014; AAG-8744-2021Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and c-ros oncogene 1 receptor tyrosine kinase gene (ROS1) alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1904 patients with lung adenocarcinoma were recorded. Results: The frequencies of EGFR mutations, ALK, and ROS1 rearrangements were 14.5%, 3.7%, and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48.7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking, and a history of asbestos exposure. Conclusions: The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis.Publication Understanding university students' smoking behaviors towards tobacco-free campus policy(Turkish Assoc Tuberculosis & Thorax, 2021-01-01) Karadag, Mehmet; Aydin Güçlü, Ozge; Gorek Dilektaşlı, Aslı; Coskun, Funda; Uzaslan, Esra; Gorek Dilektasli, Asli; GÖREK DİLEKTAŞLI, ASLI; Aydin Guclu, Ozge; AYDIN GÜÇLÜ, ÖZGE; Karadag, Mehmet; KARADAĞ, MEHMET; Coskun, Funda; COŞKUN, NECMİYE FUNDA; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-9027-1132; 0000-0003-1005-3205; 0000-0001-7099-9647; 0000-0003-3604-8826; AAG-8744-2021; AAG-9930-2019; AAD-1271-2019Introduction: Tobacco-free college campuses refer to colleges and universities that have implemented policies prohibiting the use of tobacco products at all indoor and outdoor campus locations. We aimed to evaluate university students' smoking behaviors and their attitudes towards "Tobacco-Free Campus Policy".Materials and Methods: A total of 10,383 university students were included in this cross-sectional study. The questionnaire was sent via web-based student information system. Demographical variables, the frequency of tobacco use, the addiction levels of the smoker students, and their perspective on the Tobacco-Free Campus Policy were evaluated.Results: The study population consisted of 5461 (52.6%) males and their mean age was 22.1 +/- 3.9 years. Among the students, 3992 (38.4%) were current smokers and the age of first smoking was 16.5 +/- 2.78 years. According to FTND scores, 15.1% of participants have high dependence, and 7.5% of them have very high dependence. There was a significant difference among participants who finds unacceptable "Tobacco-Free Campus Policy" in terms of gender (70.7% males vs. 29.3% females, p< 0.001) and smoking habit (7% never smoker, 4.1% ex-smoker, 88.9% current smoker, p< 0.001).Conclusion: The Tobacco-Free Campus Policy is important to fight against the tobacco industry in order to protect the right to health of all tobacco users and those who do not use it and should be considered as a goal to be achieved in order to live in a healthy environment.Publication Impact of covid-19 pneumonia on pulmonary function, functional exercise capacity and quality of life(European Respiratory Soc Journals, 2021-09-05) Dilektasli, Asli Gorek; GÖREK DİLEKTAŞLI, ASLI; Ozturk, Nilufer; ACET ÖZTÜRK, NİLÜFER AYLİN; Odabas, Ayten; Demirdogen, Ezgi; DEMİRDÖĞEN, EZGİ; Ursavas, Ahmet; URSAVAŞ, AHMET; Coskun, Funda; COŞKUN, NECMİYE FUNDA; Guclu, Ozge Aydin; AYDIN GÜÇLÜ, ÖZGE; Ediger, Dane; EDİGER, DANE; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0003-1005-3205; 0000-0002-2954-4293; AAI-3169-2021; AAE-9142-2019; JPK-7012-2023; AAD-1271-2019